2-Methyl-1-<(triphenylmethyl)amino>-2-aminopropane | 170033-56-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-Methyl-1-<(triphenylmethyl)amino>-2-aminopropane
• 英文别名: 1-(N-[(triphenyl)methyl]amino)-2-amino-2-methylpropane；1-N-(triphenylmethyl)-1,2-diamino-2-methylpropane；2-Methyl-N1-tritylpropane-1,2-diamine；2-methyl-1-N-tritylpropane-1,2-diamine
• CAS: 170033-56-4
• 化学式: C₂₃H₂₆N₂
• 分子量: 330.473
• InChiKey: YXBVEJLWQNUKOM-UHFFFAOYSA-N

物化性质

• 沸点：
  461.4±40.0 °C(Predicted)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl (S)-2-[(trifluoromethanesulfonyl)oxy]propionate 、 2-Methyl-1-<(triphenylmethyl)amino>-2-aminopropane 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-<2-Methyl-1-<(triphenylmethyl)amino>-2-propyl>-D-alanine methyl ester
  参考文献：
  名称：

  Asymmetric Synthesis of 2,6-Methylated Piperazines

  摘要：

  The complete series of enantiopure 2,6-methylated piperazines was synthesized utilizing two alternative reactions in the key bond-forming step. The dimethyl enantiomers, (2R,6R)- and (2S,6S)-2,6-dimethylpiperazine (1, 2), were prepared using either a diastereoselective triflate alkylation or a novel intramolecular Mitsunobu reaction to set the required stereochemistry. The monomethyl derivatives, (R)- and (S)-tert-butyl 2-methyl-1-piperazinecarboxylate (3, 4) were also synthesized employing the Mitsunobu cyclization strategy while the trimethyl compounds, (R)- and (S)-2,2,6-trimethylpiperazine (5, 6) were prepared using an enantiospecific triflate alkylation as the principal reaction. These methods represent efficient, general strategies for preparing a variety of 2,6-methylated piperazines for which the absolute stereochemistry can be readily controlled.

  DOI：

  10.1021/jo00118a039
• 作为产物：
  描述：

  三苯基氯甲烷 、 1,2-二氨基-2-甲基丙烷 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-Methyl-1-<(triphenylmethyl)amino>-2-aminopropane
  参考文献：
  名称：

  Use of imidazo\x9b1,5-a!quinolones as neuroprotective agents

  摘要：

  咪唑[4,5-a]喹啉（I）在治疗神经系统疾病/状况或慢性神经退行性疾病/状况方面是有用的。

  公开号：

  US05935970A1

文献信息

• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I中的苯并氧杂环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化合物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C(R7)2，（x）X1为C(R7)2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，用于抑制脂质激酶，包括p110α和PI3K的其他同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了利用Formula I中的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• Use of imidazo\x9b1,5-a!quinolones as neuroprotective agents
  申请人：Pharmacia & Upjohn Company

  公开号：US05935970A1

  公开（公告）日：1999-08-10

  The imidazo\x9b1,5-a!quinolines (I) are useful in treating neurological diseases/conditions or chronic neurodegenerative diseases/conditions.

  咪唑[4,5-a]喹啉（I）在治疗神经系统疾病/状况或慢性神经退行性疾病/状况方面是有用的。
• Imidazo[1,5-A]quinolines for treatment of anxiety and sleep disorders
  申请人：The Upjohn Company

  公开号：US05594140A1

  公开（公告）日：1997-01-14

  Imidazo[1,5-a]quinolines of formula (I) which are useful pharmaceutical agents for the treatment of anxiety, sleep disorders, panic states, convulsions and muscle disorders. ##STR1##

  Imidazo[1,5-a]quinolines的化学式（I），是用于治疗焦虑、睡眠障碍、恐慌状态、抽搐和肌肉障碍的有效药物。
• [EN] CONDENSED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2003063874A1

  公开（公告）日：2003-08-07

  A condensed heterocyclic compound having poly(adenosine 5'-diphospho-ribose)polymerase (PARP) inhibitory activity represented by the formula (I): wherein R1 is hydrogen, halogen, lower alkyl or lower alkoxy, A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, etc, -Y1=Y2- is formula (II) wherein L11, L12, L13 and L14 is (1) lower alkylene, (2) lower alkenylene, etc, and R21, R22 , R23 and R24 is (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s), etc. provided that when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, then -Y1=Y2- is formula (III) or its prodrug, or their salts.

  一种具有聚腺苷酸二磷酸核糖酶（PARP）抑制活性的缩合杂环化合物，其化学式表示为（I）：其中R1为氢、卤素、低碳基或低烷氧基，A和与A结合的六元环中的两个相邻碳原子形成苯环、吡啶环等，-Y1 = Y2-为公式（II），其中L11，L12，L13和L14为（1）低碳基烷，（2）低碳基烯烃等，R21，R22，R23和R24为（1）环状氨基，其可选地用苯基取代，该苯基可用一个或多个适当的取代基取代等。前提是当A和与A结合的六元环中的两个相邻碳原子形成苯环时，-Y1 = Y2-为公式（III）或其前药，或其盐。
• Condensed heterocyclic compounds
  申请人：Ishida Junya

  公开号：US20050080096A1

  公开（公告）日：2005-04-14

  A condensed heterocyclic compound having poly(adenosine 5′-diphospho-ribose)polymerase (PARP) inhibitory activity by the formula (I): wherein R 1 is hydrogen, halogen, lower alkyl or lower alkoxy, A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, etc, —Y 1 ═Y 2 — is formula (II) wherein L 11 , L 12 , L 13 and L 14 is (1) lower alkylene, (2) lower alkenylene, etc, and R 21 , R 22 , R 23 and R 24 is (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s), etc. provided that when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, then —Y 1 ═Y 2 — is formula (III) or its prodrug, or their salts.

  一种具有聚腺苷酸二磷酸核糖酶（PARP）抑制活性的简化杂环化合物，其化学式为（I）：其中R1为氢、卤素、低碳基或低氧基，A和要与A结合的六元环的两个相邻碳原子形成苯环、吡啶环等，—Y1═Y2—为式（II），其中L11、L12、L13和L14为（1）低碳基烷基（2）低碳基烯基等，R21、R22、R23和R24为（1）环状氨基基团，该基团被苯基取代，所述苯基可以选择一个或多个适当的取代基，等。前提是当A和要与A结合的六元环的两个相邻碳原子形成苯环时，—Y1═Y2—为式（III）或其前药或其盐。